| abstract |
Disclosed is a modified release dosage form useful for the control of hyperuricemia, gout and many other disease states. After administration to a subject in need of treatment thereof, (a) the plasma concentration of a xanthine oxidoreductase inhibitor or pharmaceutically acceptable salt thereof in the subject over a period of about 5 to about 24 hours. Maintaining above about 0.1 μg / mL and (b) maximum plasma concentration (Cmax) of xanthine oxidoreductase inhibitor or pharmaceutically acceptable salt thereof between 1.0 and 2.5 μg / mL in the subject A modified release dosage form comprising a xanthine oxidoreductase inhibitor or a pharmaceutically acceptable salt thereof, which is A controlled release dosage form using a compound as a xanthine oxidoreductase inhibitor exemplified by 2- [3-cyano-4- (3-hydroxy-methylpropoxy) phenyl] -4-methylthiazolecarboxylic acid and the like. [Selection figure] None |